News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Grant Life Sciences (GLIF.OB) And Diagnostic Technologies Ltd. Are Exploring An Expanded Partnership beyond Their Initially Proposed Association To Develop And Commercialize Grant's Cervical Cancer-Diagnostic Platform


10/30/2006 11:07:30 AM

LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences (‘Grant’) Inc. (OTC BB: GLIF) announced today that it is exploring an expanded partnership with Israel-based Diagnostic Technologies Ltd. (DTL) related to Grant’s cervical cancer-diagnostic technology. The original proposed association between the two companies, assuming acceptable due diligence by DTL, was to have been a definitive Licensing Agreement that would include an upfront licensing fee of $250,000 paid to Grant. In addition, DTL would conduct all product development at its own cost, including clinical trials, associated with the commercialization of products developed from Grant’s cervical cancer-diagnostic technology. Upon commercialization, DTL would pay Grant an ongoing royalty on sales of the products developed, according to the definitive Licensing Agreement.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES